IFITM2 antibody - 100 µg
Host : Rabbit
Clonality: Polyclonal
Clone:
Isotype: IgG
Immunogen: interferon induced transmembrane protein 2
Purity: ≥95% as determined by SDS-PAGE
Form: Liquid
Molecular weight: 15 kDa
Uniprot: Q01629
Gene id: 10581
Background: IFN-induced antiviral protein which inhibits the entry of viruses to the host cell cytoplasm, permitting endocytosis, but preventing subsequent viral fusion and release of viral contents into the cytosol. Active against multiple viruses, including influenza A virus, SARS coronavirus(SARS-CoV), Marburg virus(MARV), Ebola virus(EBOV), Dengue virus(DNV), West Nile virus(WNV), human immunodeficiency virus type 1(HIV-1) and vesicular stomatitis virus(VSV). Can inhibit: influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2-mediated viral entry, SARS-CoV S protein-mediated viral entry and VSV G protein-mediated viral entry. Induces cell cycle arrest and mediates apoptosis by caspase activation and in p53-independent manner.
Field of research: Immunology
Storage conditions: PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20°C for 12 months(Avoid repeated freeze
thaw cycles.)
Applications: ELISA, IP, IHC, IF, WB
Dilution: WB: 1:500-1:2000; IP: 1:200-1:1000; IHC: 1:20-1:200; IF: 1:20-1:200
Target: IFITM2
Purification: Immunogen affinity purified
Reactivity: Human
![]()
Clonality: Polyclonal
Clone:
Isotype: IgG
Immunogen: interferon induced transmembrane protein 2
Purity: ≥95% as determined by SDS-PAGE
Form: Liquid
Molecular weight: 15 kDa
Uniprot: Q01629
Gene id: 10581
Background: IFN-induced antiviral protein which inhibits the entry of viruses to the host cell cytoplasm, permitting endocytosis, but preventing subsequent viral fusion and release of viral contents into the cytosol. Active against multiple viruses, including influenza A virus, SARS coronavirus(SARS-CoV), Marburg virus(MARV), Ebola virus(EBOV), Dengue virus(DNV), West Nile virus(WNV), human immunodeficiency virus type 1(HIV-1) and vesicular stomatitis virus(VSV). Can inhibit: influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2-mediated viral entry, SARS-CoV S protein-mediated viral entry and VSV G protein-mediated viral entry. Induces cell cycle arrest and mediates apoptosis by caspase activation and in p53-independent manner.
Field of research: Immunology
Storage conditions: PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20°C for 12 months(Avoid repeated freeze
thaw cycles.)
Applications: ELISA, IP, IHC, IF, WB
Dilution: WB: 1:500-1:2000; IP: 1:200-1:1000; IHC: 1:20-1:200; IF: 1:20-1:200
Target: IFITM2
Purification: Immunogen affinity purified
Reactivity: Human